Please assess the completion status of the following clinical trial:

Trial Title: Everolimus on CKD Progression in ADPKD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects over 18 years of both genders~2. Clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD)~3. GFR, according to MDRD formula, between 30 and 90 ml/min/1.73 mq~4. Previous follow up of two years, with a creatinine evaluation at least once a year~5. GFR reduction of at least 2.5 ml/min/year (according to MDRD formula)~Exclusion Criteria:~1. Pregnancy, lactating, males and females without adequate contraception~2. Leucopenia (\< 3,000 leucocytes/mm3) or thrombocytopenia (\< 100,000 platelets/mm3)~3. Dyslipidemia (cholesterol or triglycerides \> 260 mg/dl with treatment)~4. Urinary tract infection~5. Patients who cannot undergoing NMR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Everolimus + standard therapy for CKD
- Control (Type: NO_INTERVENTION): Standard therapy for CKD

Based on this trial design, predict the completion outcome and termination type (if applicable).